Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SHSE:600196 Stock Report

Market Cap: CN¥65.1b

Shanghai Fosun Pharmaceutical (Group) Valuation

Is 600196 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600196 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600196 (CN¥26.24) is trading above our estimate of fair value (CN¥12)

Significantly Below Fair Value: 600196 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600196?

Key metric: As 600196 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600196. This is calculated by dividing 600196's market cap by their current earnings.
What is 600196's PE Ratio?
PE Ratio33x
EarningsCN¥2.11b
Market CapCN¥65.07b

Price to Earnings Ratio vs Peers

How does 600196's PE Ratio compare to its peers?

The above table shows the PE ratio for 600196 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.7x
600085 Beijing Tongrentang
33.3x16.4%CN¥56.1b
002422 Sichuan Kelun Pharmaceutical
16.3x11.4%CN¥50.2b
000999 China Resources Sanjiu Medical & Pharmaceutical
17.2x11.2%CN¥61.0b
000538 Yunnan Baiyao GroupLtd
24.1x11.3%CN¥106.2b
600196 Shanghai Fosun Pharmaceutical (Group)
33x30.1%CN¥65.1b

Price-To-Earnings vs Peers: 600196 is expensive based on its Price-To-Earnings Ratio (33x) compared to the peer average (22.7x).

Price to Earnings Ratio vs Industry

How does 600196's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600196 33.0xIndustry Avg. 31.1xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600196 is expensive based on its Price-To-Earnings Ratio (33x) compared to the CN Pharmaceuticals industry average (31.1x).

Price to Earnings Ratio vs Fair Ratio

What is 600196's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600196 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33x
Fair PE Ratio37.7x

Price-To-Earnings vs Fair Ratio: 600196 is good value based on its Price-To-Earnings Ratio (33x) compared to the estimated Fair Price-To-Earnings Ratio (37.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600196 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥26.24
CN¥27.69
+5.5%
14.8%CN¥34.50CN¥23.05n/a6
Nov ’25CN¥26.51
CN¥27.69
+4.5%
14.8%CN¥34.50CN¥23.05n/a6
Oct ’25CN¥27.67
CN¥27.29
-1.4%
15.4%CN¥34.50CN¥22.64n/a6
Sep ’25CN¥22.54
CN¥27.67
+22.8%
15.1%CN¥34.50CN¥22.64n/a6
Aug ’25CN¥23.60
CN¥27.87
+18.1%
14.1%CN¥34.50CN¥24.04n/a6
Jul ’25CN¥22.13
CN¥28.61
+29.3%
15.3%CN¥35.00CN¥24.50n/a6
Jun ’25CN¥23.17
CN¥28.61
+23.5%
15.3%CN¥35.00CN¥24.50n/a6
May ’25CN¥23.67
CN¥29.44
+24.4%
14.5%CN¥35.00CN¥24.50n/a6
Apr ’25CN¥23.45
CN¥31.18
+33.0%
17.5%CN¥38.70CN¥24.50n/a6
Mar ’25CN¥24.77
CN¥32.03
+29.3%
15.6%CN¥38.70CN¥24.50n/a6
Feb ’25CN¥22.27
CN¥32.94
+47.9%
11.9%CN¥38.70CN¥28.68n/a6
Jan ’25CN¥25.03
CN¥33.57
+34.1%
10.3%CN¥38.70CN¥30.00n/a6
Dec ’24CN¥27.98
CN¥33.57
+20.0%
10.3%CN¥38.70CN¥30.00n/a6
Nov ’24CN¥28.22
CN¥33.91
+20.1%
9.7%CN¥38.70CN¥30.00CN¥26.516
Oct ’24CN¥28.60
CN¥36.65
+28.1%
28.0%CN¥54.00CN¥19.04CN¥27.676
Sep ’24CN¥28.01
CN¥37.41
+33.6%
25.1%CN¥54.00CN¥19.04CN¥22.547
Aug ’24CN¥31.53
CN¥40.24
+27.6%
18.1%CN¥54.00CN¥28.69CN¥23.607
Jul ’24CN¥30.90
CN¥40.95
+32.5%
17.3%CN¥54.00CN¥28.69CN¥22.137
Jun ’24CN¥30.60
CN¥40.95
+33.8%
17.3%CN¥54.00CN¥28.69CN¥23.177
May ’24CN¥31.70
CN¥41.08
+29.6%
16.3%CN¥54.00CN¥28.69CN¥23.678
Apr ’24CN¥32.39
CN¥40.96
+26.5%
16.4%CN¥54.00CN¥28.69CN¥23.458
Mar ’24CN¥33.97
CN¥41.88
+23.3%
16.5%CN¥54.00CN¥30.94CN¥24.777
Feb ’24CN¥34.23
CN¥43.59
+27.3%
17.6%CN¥54.00CN¥30.94CN¥22.277
Jan ’24CN¥35.24
CN¥44.31
+25.7%
19.8%CN¥59.00CN¥30.94CN¥25.037
Dec ’23CN¥36.23
CN¥44.52
+22.9%
21.2%CN¥59.00CN¥30.94CN¥27.986
Nov ’23CN¥34.39
CN¥45.43
+32.1%
22.3%CN¥59.00CN¥30.94CN¥28.225

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥50.2b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.49

7D

-2.1%

1Y

7.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.7b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.25

7D

-1.7%

1Y

16.8%